34 results about "Heparinoid" patented technology

Provided is a chemically modified bovine intestinal heparin, as well as pharmaceutical compositions, compositions comprising chemically modified bovine intestinal heparin, and methods for making and using the same.

To provide a thymic stromal lymphopoietin expression inhibitor, an external composition for skin or the like that can inhibit the expression of thymic stromal lymphopoietin (TSLP).SOLUTION: The present invention provides a thymic stromal lymphopoietin expression inhibitor, an external composition for skin or the like, comprising at least one selected from a mannuronic acid oligomer methylsilanol ester, a heparinoid, and a middle-molecular-weight hyaluronic acid having a molecular weight of 50,000 or more and 400,000 or less.SELECTED DRAWING: None

Provided is a bovine intestinal heparin chemically modified with a 1-(3-dimethylaminopropyl)-3-ethylurea (EDU)-amide having anti-factor IIA activity is about 20 to about 30 IU / mg, wherein the modified bovine intestinal heparin exhibits between 20% and 50% of the anti-factor IIa activity of the nonchemically modified bovine intestinal heparin, as well as pharmaceutical compositions, compositions comprising chemically modified bovine intestinal heparin, and methods for making and using the same

The utility model relates to the technical field of heparin processing, in particular to heparinoid processing and purifying equipment, which comprises an ion exchange resin cylinder and a purifying cylinder, a filter screen frame is mounted at the upper end of the ion exchange resin cylinder through a mounting rack, ion exchange resin is arranged in the ion exchange resin cylinder, and the purifying cylinder is mounted on the filter screen frame. A purification cylinder is arranged at one end of the ion exchange resin cylinder, a top cover is clamped at the top of the purification cylinder, a glass observation opening is embedded in one side of the purification cylinder, an electric heater is mounted on one side of the bottom end of the glass observation opening through a mounting hole, and a temperature controller is mounted at the upper end of the electric heater through a screw; a through guide sleeve is arranged at one end of the top of the top cover, and a metal material taking straight pipe is arranged in the through guide sleeve in a sleeved mode. According to the heparinoid processing and purifying equipment, the supernate and the heparinoid-containing precipitate can be conveniently and rapidly separated and subjected to evaporation and dehydration treatment, water and organic solvents in the supernate and the heparinoid-containing precipitate are removed, the processing efficiency is improved, and manpower and material resources are saved.

The present application belongs to the field of biotechnology, and particularly relates to a co-production process for extracting heparin, heparan, chondroitin, hyaluronic acid and protein from lung. The present application adopts FPA98 CL type strong base anion exchange resin suitable for adsorption of glycosaminoglycan to adsorb heparin, heparan, chondroitin and hyaluronic acid, and different concentrations of sodium chloride solution are used to stepwise elute heparin, heparan, chondroitin and hyaluronic acid due to different binding abilities of heparin, heparan, chondroitin and hyaluronic acid to the resin. In addition, in order to improve the distinguishing ability of chondroitin and hyaluronic acid, sulfur trioxide aeration treatment is carried out before enzymolysis. Through the process of the present application, the co-production of heparin, heparan, chondroitin, hyaluronic acid and protein is successfully realized, and has good application prospect.

The present invention is directed to hexasaccharides mimetics of heparins presenting remarkable heparanase inhibition activity. The compounds have formula (I), wherein R1 is selected from the group consisting of NH2, NHSO3Na, NHAc; R2 is selected from the group consisting of NH2, NHSO3Na, NHAc; R3 is selected from the group consisting of Bn, H; R4 is selected from the group consisting of Ac, H, SO3Na; R5 is CO2Na; R6 is selected from the group consisting of Me, Ethyl, Alkyl, alkyl azide, alkynyl, cholestanol aglycon; R7 is selected from the group consisting of CH2OH, COOH.

Provided is a method by which a heparin-like substance having higher activity can be produced. The present invention provides a method for producing a heparin-like substance, the method comprising the steps of: (1) preparing a mammalian cell that produces a heparin-like substance; and (2) culturing the mammalian cell prepared in the step (1), which produces the heparin-like substance, at a temperature effective for suppressing cell proliferation, and causing the mammalian cell to produce the heparin-like substance. The temperature effective for suppressing proliferation is preferably a temperature which is 2 to 14°C lower than the optimum temperature for the proliferation.

The invention discloses preparation and application of toad skin heparinoid sulfate capable of inhibiting activity of new spike protein. The preparation method comprises the following steps: crushing dried toad skin, heating in a water bath to swell, carrying out enzymolysis by using alkaline protease, and carrying out alcohol precipitation, anion exchange column purification, dialysis and freeze drying to obtain a toad skin glycosaminoglycan crude extract; crude toad skin glycosaminoglycan extracts are subjected to enzymolysis through chondroitin sulfate ABC enzyme, and the toad skin heparinoid sulfate is obtained through gel chromatographic column purification, desalination and freeze drying. The average molecular weight of the toad skin heparinoid sulfate is 11Kda, the toad skin heparinoid sulfate is composed of disaccharide units formed by connecting hexuronic acid and glucosamine through 1-4 glucosidic bonds, and the total sulfation degree of the C-2-oxygen site of hexuronic acid and the total sulfation degree of the C-6-oxygen site and the total sulfation degree of the N-site of glucosamine are 11.45%, 33.68% and 46.46% respectively. The toad skin heparinoid sulfate has competitive activity of inhibiting binding of new crown spike protein and heparin, and can prevent initial infection of new crown virus. The invention lays an important foundation for the development of new clinical application of the toad skin.

A heparin-like ternary copolymer containing zwitterionic, sulfonic, and carboxyl side chains is prepared by atom transfer radical polymerization (ATRP) from a first monomer containing a sulfonic acid group and an olefinic group, a second monomer containing an oxygen-carbon chain-linked zwitterionic group and an olefinic group, and a third monomer containing an oxygen-carbon chain-linked carboxyl side chain and an olefinic group. This ternary copolymer has a heparin-like structure and utilizes zwitterionic groups that mimic the hydrophilicity of cell membrane lecithin and negatively charged sulfonic acid groups with anticoagulant activity to inhibit both intrinsically and exogenously induced coagulation reactions. Anticoagulant coatings prepared from this copolymer can largely address the problem of zwitterionic polymers alone having poor anticoagulant properties and being unable to meet the anticoagulant requirements of biomedical devices. It also provides an effective solution to the multiple side effects and adverse reactions that systemic anticoagulants are prone to.

The invention discloses a green synthesis method of heparinoid, and relates to the technical field of biological medicine, and the green synthesis method comprises the following steps: S1, dissolving microorganism source chondroitin sulfate in a DES solvent; s2, adding the immobilized sulfotransferase, and carrying out a stirring reaction; and S3, filtering the reaction liquid, freezing the filtrate, and drying to obtain heparinoid powder. The whole reaction is carried out under mild conditions, the conversion rate is high, the reaction time is short, the production efficiency is improved, the use of an organic solvent is reduced through the integrated purification technology, the environmental pollution is reduced, meanwhile, the operation steps are simplified, the production cost is reduced, the high purity of heparinoid is ensured, impurity residues are reduced, and the product quality is improved.

To provide a skin care preparation effective for improving skin elasticity and / or improving flabby skin.SOLUTION: The heparinoid is used as an active ingredient of a skin care preparation for external use effective for improving skin elasticity and / or improving sagging skin.SELECTED DRAWING: None

This invention discloses a qualitative and quantitative analysis method for heparin-like components in the biopharmaceutical field. The method includes using a liquid chromatograph, an SAX strong anion exchange column, sodium dihydrogen phosphate solution as mobile phase A, and mobile phase B consisting of mobile phase A containing sodium perchlorate, with gradient elution for monitoring and analysis. This invention improves the separation of heparin-like components by screening chromatographic packing materials, optimizing the chromatographic method, and optimizing the detection wavelength. It allows for accurate qualitative analysis of up to five heparin components using a simple liquid chromatography method. Furthermore, this invention incorporates the simulated separation function of the Glycomapping glycosylation software to reconstruct the elution peaks of components that do not reach baseline separation, and then achieves quantitative analysis of each separated component based on the external standard method. This qualitative and quantitative analysis method provides a feasible solution for component identification and content determination in heparin-like samples, and offers an important means for heparin quality control.

The application discloses a kind of white snail glycosaminoglycan-growth factor composite active substance directional extraction purification process, belong to biological active substance extraction technical field.Core breakthrough is in at: through-10 ℃ acetone circulation degreasing and 20kHz ultrasonic coordination papain-neutral protease compound system (mass ratio 1:0.8), realize glycosaminoglycan and growth factor synchronous efficient release, extraction rate reaches 97.2%;Using DEAE-Sepharose Fast Flow and Q Sepharose Fast Flow double column chromatography gradient elution, combined with 1000Da ultrafiltration membrane refining, composite active substance purity is ≥99.6%;Through-Vc mild depolymerization technology regulates glycosaminoglycan molecular weight to 3.8~23.8kDa, retains its heparin-like structure activity;Using porous medium enhanced vacuum freeze-drying process, so that composite active substance activity retention rate is ≥98.5%.Product glycosaminoglycan content is ≥35mg / g, growth factor (EGF class) activity is ≥1200IU / mg, DPPH free radical clearance rate is ≥65%, to skin fibroblast proliferation promotion rate is ≥72%, no organic solvent residue and heavy metal pollution.

The invention belongs to the technical field of biology, and particularly relates to a salivary protein of a ptyas ptyas and application thereof. According to the specific technical scheme, the salivary protein of the ptyas ptyas is Pmen1, Pmen2, Pmen3 or Pmen4. The new sialoprotein is screened and obtained from the oral gland product of the Menglian snake, the sialoprotein is greatly different from known heparinase and heparanase, but the sialoprotein can hydrolyze heparin, and the sialoprotein has good application value in research on hydrolysis of heparin, heparan sulfate and other heparinoids. Certain development potential is realized in the fields of anti-tumor and anti-virus treatment, anticoagulant development, precise drug delivery and the like.

This invention discloses a heparin sulfate derivative derived from donkey-hide gelatin with inhibitory activity against the SARS-CoV-2 spike protein and its preparation method. The heparin sulfate derivative is prepared by first enzymatically hydrolyzing a donkey-hide gelatin solution with streptomycin, followed by separation and purification using DEAE anion exchange chromatography to obtain donkey-hide gelatin glycosaminoglycans. These glycosaminoglycans are then enzymatically hydrolyzed again using chondroitin sulfate ABC enzyme, followed by separation and purification using DEAE anion exchange chromatography. The derivative has an average molecular weight of 13.2 kDa and is composed of disaccharide units linked by hexuronic acid and glucosamine via 1-4 glycosidic bonds. The total sulfation degrees at the C-2-O position of hexuronic acid, the C-6-O position of glucosamine, and the N-position are 28.2%, 44.3%, and 38.9%, respectively. This heparin sulfate derivative exhibits competitive inhibition of the binding activity between the SARS-CoV-2 spike protein and heparin, enabling effective prevention of early-stage SARS-CoV-2 infection and laying an important foundation for developing new clinical applications of donkey-hide gelatin.

To improve the stability of a heparin analog in an external composition containing the heparin analog.SOLUTION: An external composition contains (A) a heparin analog, and (B) at least one amino acid component selected from the group consisting of tranexamic acid and a salt thereof, acylamino acid, a derivative thereof and a salt thereof, arginine, a derivative thereof and a salt thereof, lysine, a derivative thereof and a salt thereof.SELECTED DRAWING: None

A carbonated aerosol external preparation for skin, including a stock solution containing the following components (A) to (C), and a propellant containing the following component (D): (A) heparinoid, (B) water-soluble polymer, (C) water, and (D) carbon dioxide gas. The carbonated aerosol external preparation for skin has a pH immediately after discharge of 4.0 or more and 7.0 or less. The component (B) includes one or more selected from the group consisting of hydroxypropylmethylcellulose and acrylic acid / alkyl (meth)acrylate copolymer. A content of the component (B) in the stock solution is from 0.05 to 5.0% by mass, based on a total mass of the stock solution.

To provide a topical pharmaceutical composition containing indomethacin, diclofenac sodium, felbinac, salicylic acids, or heparins, wherein irritation to the application site is reduced. [Solution] A topical pharmaceutical composition that contains component (A) and component (B) below, wherein component (A) is one or more selected from the group consisting of components (A-1) to (A-5) below, and which reduces irritation to the application site. Ingredient (A-1): Indomethacin Ingredient (A-2): Diclofenac sodium Ingredient (A-3): Felbinac Ingredients (A-4): Salicylic acids Ingredient (A-5): Heparinoid Ingredient (B): One or more selected from the group consisting of loxoprofen, its salts, and their hydrates.

This invention discloses a heparin-like hydrogel microsphere for melanoma postoperative wound repair, its preparation method, and its application, belonging to the field of medical dressing technology. The preparation of the heparin-like hydrogel microsphere for melanoma postoperative wound repair includes the following steps: dissolving KOSMA and GelMA in water to prepare a GelMA solution; adding a photoinitiator to form a precursor hydrogel solution; using the precursor hydrogel solution as the dispersed phase and castor oil as the continuous phase to prepare hydrogel microspheres; collecting the effluent; exposing it to ultraviolet light for curing; washing; and drying to obtain the final product. When used for melanoma postoperative wound care, these hydrogel microspheres can safely promote wound healing, specifically eliminate residual tumor cells, reduce the postoperative local recurrence rate, and can also serve as drug carriers to achieve synergistic therapeutic effects; providing new research ideas and technical strategies for integrated care of melanoma postoperative wounds and tumor prevention and control.

The application discloses an enhanced anti-coagulation and anti-bacterial hemodialysis hollow fiber membrane and a preparation method thereof, and belongs to the technical field of medical membrane materials. The acid activation-polydopamine coating-sulfonated grafting modification of halloysite nanotubes is carried out in the application, so that the surface sulfonic acid group density of the halloysite nanotubes reaches 0.8-2.1 mmol / g, and the Zeta potential is less than or equal to-30 mV. The modified halloysite is dispersed in a polar aprotic solvent in advance, is incorporated into a polymer matrix after ultrasonic treatment, is filtered through a sintering filter element with a diameter of less than or equal to 5 mu m, is defoamed, is spun by using a dry spraying-wet spinning method, and is prepared into a finished product through coagulation, rinsing and drying. The application constructs a heparin-like negative charge layer, so that the activated partial thromboplastin time (APTT) is greater than or equal to 55 s, platelet adhesion and protein adsorption are significantly inhibited, and the application has a broad-spectrum antibacterial performance. The rigid halloysite induces the formation of through channels, so that the pain point that a high-flux membrane is easy to damage red blood cells is solved, the process is stable, and the application is suitable for industrial production.

To provide a topical preparation for skin exhibiting superior usability even when containing active ingredients including niacinamide, dipotassium glycyrrhizate, or heparinoid, as well as an oily component and a surfactant.SOLUTION: A topical preparation for skin characterized by comprising (A) niacinamide, (B) dipotassium glycyrrhizate, (C) a heparinoid, (D) an oily component, (E) a surfactant, and (F) a divalent alcohol.SELECTED DRAWING: None

The object of this disclosure is to provide a topical composition comprising ceramide 2 and isopropyl myristate that can suppress creaming. [Solution] A topical composition containing (A) ceramide 2, (B) isopropyl myristate, and (C) heparinoid has suppressed creaming.

A composition for external use comprising (A) an ascorbic acid compound, derivatives and salts thereof; (B) an edetic acid salt; (C) a glycyrrhizic acid salt; (D) a heparinoid; and (E) water and an ascorbic acid compound-containing composition for external use in which precipitation under low-temperature storage conditions is suppressed.

The invention relates to the technical field of biological pharmacy, in particular to a method for extracting heparinoid from heparin sodium alcohol precipitation alcohol, which comprises the following steps: S1, pretreatment: filtering the collected heparin sodium alcohol precipitation alcohol to obtain clear filtrate; s2, concentration: concentrating the clarified filtrate in a reduced pressure distillation manner, and stopping distillation when the clarified filtrate is concentrated to 1 / 5-1 / 3 of the original volume to obtain a concentrated solution; s3, precipitation: slowly adding acetone into the concentrated solution while stirring, and precipitating and separating out the heparinoid to obtain a solid-liquid mixture. According to the method, a large amount of waste alcohol precipitation alcohol generated in the heparin sodium production process is deeply developed, the heparinoid product with the high additional value is extracted, waste of heparinoid resources is greatly reduced, and the economic benefits of enterprises are improved; meanwhile, organic substances in the waste liquid are recycled, so that the chemical oxygen demand of the discharged waste liquid is effectively reduced, the subsequent sewage treatment cost is reduced, and good environmental benefits are achieved.

The application belongs to the technical field of medicine and cosmetics, and relates to a kind of ultra-low molecular weight heparin fusion molecules and its preparation method and application.The structure is as shown in formula I, wherein x is greater than or equal to 0, y is greater than or equal to 1;R1 and R2 are each independently selected from -SO3Na or -H;R3 is;Weight average molecular weight is 3-4kDa.The structure of the ultra-low molecular weight heparin fusion molecule provided by the application contains hydrophobic amide thiazole resorcinol structure and hydrophilic ultra-low molecular weight heparin structure at the same time, which are combined by covalent ester bond, has higher safety and excellent water solubility, and improves the problems of poor water solubility of amide thiazole resorcinol and safety risk of heparin products used in cosmetics.

This invention provides a natural rubber anticoagulant and latex-expelling accelerator and its application. The accelerator includes an anticoagulant, a cut repair agent, and an active stabilizer. The anticoagulant is a citrate, heparin ammonium salt, or dithiothreon derivative; the cut repair agent is a phenylurea derivative; and the active stabilizer is at least one of sorbitol, phenacetin, polyvinylpyrrolidone, and sodium octaborate tetrahydrate. The accelerator of this invention is safer and more efficient when applied to rubber tree tapping, promoting latex excretion and tree recovery, effectively saving bark consumption, significantly reducing ethylene stimulation concentration, effectively reducing the side effects of ethylene, obtaining ideal yield, accelerating the repair of cut bark, and reducing the risk of pathogen infection of wounds.

The present application relates to sewage biological technology field, disclose a kind of resource processing method of activated sludge.The resource processing method of activated sludge includes the following steps: washing activated sludge obtains sediment sludge;Sediment sludge is mixed with water to obtain suspension, suspension is digested, and first supernatant and sludge residue are obtained by separation;First supernatant is impurity-removed by calcium salt solution and alcohol solvent to obtain first precipitate;First precipitate is dissolved and separated to obtain second supernatant;Second supernatant is impurity-removed by alcohol solvent to obtain second precipitate;Second precipitate is dissolved and separated to obtain third precipitate;Third precipitate is dissolved and separated to obtain third supernatant, and third supernatant is impurity-removed by alcohol solvent to obtain fourth precipitate;Fourth precipitate is purified to obtain heparinoid polysaccharide.This method has good impurity-removing effect, high polysaccharide yield, and the sludge residue obtained by separation can be used for fermentation to produce methane, and the heparinoid polysaccharide obtained has similar blood clotting function and anticancer potential to commercially available heparin, and has high application value.

Provided is a chemically modified bovine intestinal beparin, as well as pharmaceutical compositions, compos itions comprising chemically modified bovine intestinal heparin, and methods for making and using the same.

An aerosol carbonic acid skin external preparation, which is composed of an aerosol base liquid containing components (A) to (C) and a propellant containing component (D), and has a pH value of 4.0 or more and 7.0 or less immediately after being sprayed. (A) heparinoid, (B) water-soluble polymer, (C) water, (D) carbon dioxide.

Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.